Antioxidant Supplement, Market Research Report

Los Angeles, United States, July 1, 2020, The report on the global Antioxidant Supplement, market is comprehensively prepared with main focus on the competitive landscape, geographical growth, segmentation, and market dynamics, including drivers, restraints, and opportunities. It sheds light on key production, revenue, and consumption trends so that players could improve their sales and growth in the Global Antioxidant Supplement, Market. It offers a detailed analysis of the competition and leading companies of the global Antioxidant Supplement, market. Here, it concentrates on the recent developments, sales, market value, production, gross margin, and other important factors of the business of top players operating in the global Antioxidant Supplement, market.

With deep quantitative and qualitative analysis, the report provides encyclopedic and accurate research study on important aspects of the global Antioxidant Supplement, market. It brings to light key factors affecting the growth of different segments and regions in the global Antioxidant Supplement, market. It also offers SWOT, Porters Five Forces, and PESTLE analysis to thoroughly examine the global Antioxidant Supplement, market. It gives a detailed study on manufacturing cost, upstream and downstream buyers, distributors, marketing strategy, and marketing channel development trends of the global Antioxidant Supplement, market. Furthermore, it provides strategic bits of advice and recommendations for players to ensure success in the global Antioxidant Supplement, market.

Some of the Important Key player operating in this Report are: NOW, Vibrant Health, AST R-ALA, GNC, Jarrow Formulas, Life Extension, Antioxidant Supplement

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1833496/covid-19-impact-on-global-antioxidant-supplement-market

Segmental Analysis

The report has classified the global Antioxidant Supplement, industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Antioxidant Supplement, manufacturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Railway Signaling System industry.

Antioxidant Supplement, Segmentation by Product

, Medical Grade, Food Grade Antioxidant Supplement

Antioxidant Supplement, Segmentation by Application

, Medical, Food, Cosmetics

Regions and Countries

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Key Questions Answered

What is the size and CAGR of the global Antioxidant Supplement, market?

Which are the leading segments of the global Antioxidant Supplement, market?

What are the key driving factors of the most profitable regional market?

What is the nature of competition in the global Antioxidant Supplement, market?

How will the global Antioxidant Supplement, market advance in the coming years?

What are the main strategies adopted in the global Antioxidant Supplement, market?

Get Full Report in your Inbox within 24 hours Now at(3900) @ https://www.qyresearch.com/settlement/pre/a7c1e7ce9053c8600b91d589b8f50257,0,1,covid-19-impact-on-global-antioxidant-supplement-market

Table of Contents

1 Study Coverage1.1 Antioxidant Supplement Product Introduction1.2 Market Segments1.3 Key Antioxidant Supplement Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Antioxidant Supplement Market Size Growth Rate by Type1.4.2 Medical Grade1.4.3 Food Grade1.5 Market by Application1.5.1 Global Antioxidant Supplement Market Size Growth Rate by Application1.5.2 Medical1.5.3 Food1.5.4 Cosmetics1.6 Coronavirus Disease 2019 (Covid-19): Antioxidant Supplement Industry Impact1.6.1 How the Covid-19 is Affecting the Antioxidant Supplement Industry1.6.1.1 Antioxidant Supplement Business Impact Assessment Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Antioxidant Supplement Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-191.6.3.1 Government Measures to Combat Covid-19 Impact1.6.3.2 Proposal for Antioxidant Supplement Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Executive Summary2.1 Global Antioxidant Supplement Market Size Estimates and Forecasts2.1.1 Global Antioxidant Supplement Revenue 2015-20262.1.2 Global Antioxidant Supplement Sales 2015-20262.2 Antioxidant Supplement Market Size by Region: 2020 Versus 20262.2.1 Global Antioxidant Supplement Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Antioxidant Supplement Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Antioxidant Supplement Competitor Landscape by Players3.1 Antioxidant Supplement Sales by Manufacturers3.1.1 Antioxidant Supplement Sales by Manufacturers (2015-2020)3.1.2 Antioxidant Supplement Sales Market Share by Manufacturers (2015-2020)3.2 Antioxidant Supplement Revenue by Manufacturers3.2.1 Antioxidant Supplement Revenue by Manufacturers (2015-2020)3.2.2 Antioxidant Supplement Revenue Share by Manufacturers (2015-2020)3.2.3 Global Antioxidant Supplement Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Antioxidant Supplement Revenue in 20193.2.5 Global Antioxidant Supplement Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Antioxidant Supplement Price by Manufacturers3.4 Antioxidant Supplement Manufacturing Base Distribution, Product Types3.4.1 Antioxidant Supplement Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Antioxidant Supplement Product Type3.4.3 Date of International Manufacturers Enter into Antioxidant Supplement Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Antioxidant Supplement Market Size by Type (2015-2020)4.1.1 Global Antioxidant Supplement Sales by Type (2015-2020)4.1.2 Global Antioxidant Supplement Revenue by Type (2015-2020)4.1.3 Antioxidant Supplement Average Selling Price (ASP) by Type (2015-2026)4.2 Global Antioxidant Supplement Market Size Forecast by Type (2021-2026)4.2.1 Global Antioxidant Supplement Sales Forecast by Type (2021-2026)4.2.2 Global Antioxidant Supplement Revenue Forecast by Type (2021-2026)4.2.3 Antioxidant Supplement Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Antioxidant Supplement Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global Antioxidant Supplement Market Size by Application (2015-2020)5.1.1 Global Antioxidant Supplement Sales by Application (2015-2020)5.1.2 Global Antioxidant Supplement Revenue by Application (2015-2020)5.1.3 Antioxidant Supplement Price by Application (2015-2020)5.2 Antioxidant Supplement Market Size Forecast by Application (2021-2026)5.2.1 Global Antioxidant Supplement Sales Forecast by Application (2021-2026)5.2.2 Global Antioxidant Supplement Revenue Forecast by Application (2021-2026)5.2.3 Global Antioxidant Supplement Price Forecast by Application (2021-2026) 6 North America6.1 North America Antioxidant Supplement by Country6.1.1 North America Antioxidant Supplement Sales by Country6.1.2 North America Antioxidant Supplement Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America Antioxidant Supplement Market Facts & Figures by Type6.3 North America Antioxidant Supplement Market Facts & Figures by Application 7 Europe7.1 Europe Antioxidant Supplement by Country7.1.1 Europe Antioxidant Supplement Sales by Country7.1.2 Europe Antioxidant Supplement Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe Antioxidant Supplement Market Facts & Figures by Type7.3 Europe Antioxidant Supplement Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific Antioxidant Supplement by Region8.1.1 Asia Pacific Antioxidant Supplement Sales by Region8.1.2 Asia Pacific Antioxidant Supplement Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific Antioxidant Supplement Market Facts & Figures by Type8.3 Asia Pacific Antioxidant Supplement Market Facts & Figures by Application 9 Latin America9.1 Latin America Antioxidant Supplement by Country9.1.1 Latin America Antioxidant Supplement Sales by Country9.1.2 Latin America Antioxidant Supplement Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America Antioxidant Supplement Market Facts & Figures by Type9.3 Central & South America Antioxidant Supplement Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa Antioxidant Supplement by Country10.1.1 Middle East and Africa Antioxidant Supplement Sales by Country10.1.2 Middle East and Africa Antioxidant Supplement Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 U.A.E10.2 Middle East and Africa Antioxidant Supplement Market Facts & Figures by Type10.3 Middle East and Africa Antioxidant Supplement Market Facts & Figures by Application 11 Company Profiles11.1 NOW11.1.1 NOW Corporation Information11.1.2 NOW Description, Business Overview and Total Revenue11.1.3 NOW Sales, Revenue and Gross Margin (2015-2020)11.1.4 NOW Antioxidant Supplement Products Offered11.1.5 NOW Recent Development11.2 Vibrant Health11.2.1 Vibrant Health Corporation Information11.2.2 Vibrant Health Description, Business Overview and Total Revenue11.2.3 Vibrant Health Sales, Revenue and Gross Margin (2015-2020)11.2.4 Vibrant Health Antioxidant Supplement Products Offered11.2.5 Vibrant Health Recent Development11.3 AST R-ALA11.3.1 AST R-ALA Corporation Information11.3.2 AST R-ALA Description, Business Overview and Total Revenue11.3.3 AST R-ALA Sales, Revenue and Gross Margin (2015-2020)11.3.4 AST R-ALA Antioxidant Supplement Products Offered11.3.5 AST R-ALA Recent Development11.4 GNC11.4.1 GNC Corporation Information11.4.2 GNC Description, Business Overview and Total Revenue11.4.3 GNC Sales, Revenue and Gross Margin (2015-2020)11.4.4 GNC Antioxidant Supplement Products Offered11.4.5 GNC Recent Development11.5 Jarrow Formulas11.5.1 Jarrow Formulas Corporation Information11.5.2 Jarrow Formulas Description, Business Overview and Total Revenue11.5.3 Jarrow Formulas Sales, Revenue and Gross Margin (2015-2020)11.5.4 Jarrow Formulas Antioxidant Supplement Products Offered11.5.5 Jarrow Formulas Recent Development11.6 Life Extension11.6.1 Life Extension Corporation Information11.6.2 Life Extension Description, Business Overview and Total Revenue11.6.3 Life Extension Sales, Revenue and Gross Margin (2015-2020)11.6.4 Life Extension Antioxidant Supplement Products Offered11.6.5 Life Extension Recent Development11.1 NOW11.1.1 NOW Corporation Information11.1.2 NOW Description, Business Overview and Total Revenue11.1.3 NOW Sales, Revenue and Gross Margin (2015-2020)11.1.4 NOW Antioxidant Supplement Products Offered11.1.5 NOW Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 Antioxidant Supplement Market Estimates and Projections by Region12.1.1 Global Antioxidant Supplement Sales Forecast by Regions 2021-202612.1.2 Global Antioxidant Supplement Revenue Forecast by Regions 2021-202612.2 North America Antioxidant Supplement Market Size Forecast (2021-2026)12.2.1 North America: Antioxidant Supplement Sales Forecast (2021-2026)12.2.2 North America: Antioxidant Supplement Revenue Forecast (2021-2026)12.2.3 North America: Antioxidant Supplement Market Size Forecast by Country (2021-2026)12.3 Europe Antioxidant Supplement Market Size Forecast (2021-2026)12.3.1 Europe: Antioxidant Supplement Sales Forecast (2021-2026)12.3.2 Europe: Antioxidant Supplement Revenue Forecast (2021-2026)12.3.3 Europe: Antioxidant Supplement Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Antioxidant Supplement Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Antioxidant Supplement Sales Forecast (2021-2026)12.4.2 Asia Pacific: Antioxidant Supplement Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Antioxidant Supplement Market Size Forecast by Region (2021-2026)12.5 Latin America Antioxidant Supplement Market Size Forecast (2021-2026)12.5.1 Latin America: Antioxidant Supplement Sales Forecast (2021-2026)12.5.2 Latin America: Antioxidant Supplement Revenue Forecast (2021-2026)12.5.3 Latin America: Antioxidant Supplement Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Antioxidant Supplement Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Antioxidant Supplement Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Antioxidant Supplement Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Antioxidant Supplement Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Antioxidant Supplement Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Antioxidant Supplement Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

See the original post here:
Antioxidant Supplement, Market Study for 2020 to 2026 Providing Information on Key Players, Growth Drivers and Industry Challenges|Vibrant Health, AST...

Recommendation and review posted by Bethany Smith

Florida has enacted House Bill 1189, which prohibits life and long-term care insurers from canceling, limiting, or denying coverage or adjusting premium rates based on genetic information.

As we previously reported, the bill amends Florida Statute 627.4301, which currently prohibits health insurers use of genetic information for insurance purposes. As amended, the statute removes former carve-outs for life, disability, and long-term care insurers, but certain carve-outs remain, such as those for accident-only policies, hospital indemnity or fixed indemnity policies, dental policies, and vision policies. The amended statute further provides that, in the absence of a diagnosis of a condition related to genetic information, life and long-term care insurers may not cancel, limit, or deny coverage or establish differentials in premium rates, based on such information. Additionally, those insurers are prohibited from requiring or soliciting genetic information, using genetic test results, or considering a persons decisions or actions relating to genetic testing in any manner for any insurance purpose.

It is worth noting that prior to final passage, the bill was amended to include language instructing that it should not be construed as to prevent a life or long-term care insurer from accessing an individuals medical record as part of an application exam or from considering a medical diagnosis included in an individuals medical record, even if a diagnosis was made based on the results of a genetic test. Nonetheless, the amended statute will likely prevent life insurers and long-term care insurers from asking about or obtaining the results from direct-to-consumer genetic tests.

See the original post here:
Florida Bill Restricting Life Insurers' Use of Genetic Information Signed by Governor DeSantis - Lexology

Recommendation and review posted by Bethany Smith

It is our aim to provide our readers with report for Direct-to-Consumer Genetic Testing (DTC-GT) Market, which examines the industry during the period 2020 2026. One goal is to present deeper insight into this line of business in this document. The first part of the report focuses on providing the industry definition for the product or service under focus in the Direct-to-Consumer Genetic Testing (DTC-GT) Market report. Next, the document will study the factors responsible for hindering and enhancing growth in the industry. After covering various areas of interest in the industry, the report aims to provide how the Direct-to-Consumer Genetic Testing (DTC-GT) Market will grow during the forecast period.

The major vendors covered:

Family Tree DNA, MyHeritage, EasyDNA, Ancestry.com LLC, 24Genetics, Dante Labs, Atlas Biomed, Genebase, Mapmygenome and more

The final report will add the analysis of the Impact of Covid-19 on Direct-to-Consumer Genetic Testing (DTC-GT) Market.

Request a free sample copy @ https://www.reportsandmarkets.com/sample-request/direct-to-consumer-genetic-testing-dtc-gt-global-market-status-and-trend-report-2013-2023?utm_source=jewishlifenews&utm_medium=38

The Direct-to-Consumer Genetic Testing (DTC-GT) Market report between the years 2020 2026 will highlight the current value of the industry. At the same time, there is also an estimate of how much this line of business will be worth at the end of the forecast period. As it is our goal to maintain high levels of accuracy at all times, we will take a look at the CAGR of the Direct-to-Consumer Genetic Testing (DTC-GT) Market. We make sure that all the information available in this report has excellent levels of readability. One way we achieve this target is by Direct-to-Consumer Genetic Testing (DTC-GT) Market segmentation. Going through the report for 2020 2026 will bring our readers up-to-date regarding this industry.

While examining the information from this document, one thing becomes clear, the elements which contribute to increase in demand for the product or service. At the same time, there will be a focus on what drives the popularity of these types of products or services. This report is for those who want to learn about Direct-to-Consumer Genetic Testing (DTC-GT) Market, along with its forecast for 2020 2026. Information regarding market revenue, competitive partners, and key players will also be available.

Segmentation

As discussed earlier, there is segmentation in the Direct-to-Consumer Genetic Testing (DTC-GT) Market report, to improve the accuracy and make it easier to collect data. The categories which are the dividing factors in the industry are distribution channels, application, and product or service type. With this level of segmentation, it becomes easier to analyze and understand the Direct-to-Consumer Genetic Testing (DTC-GT) Market. At the same time, there is emphasis on which type of consumers become the customers in this industry. When it comes to distribution channels, the Direct-to-Consumer Genetic Testing (DTC-GT) Market report looks at the different techniques of circulation of the product or service.

Regional Overview

In this part of the Direct-to-Consumer Genetic Testing (DTC-GT) Market report, we will be taking a look at the geographical areas and the role they play in contributing to the growth of this line of business. The areas of interest in this document are as follows Middle East and Africa, South and North America, Europe, and Asia Pacific. From the Direct-to-Consumer Genetic Testing (DTC-GT) Market report, it becomes clear which region is the largest contributor.

Latest Industry News

From this Direct-to-Consumer Genetic Testing (DTC-GT) Market report, the reader will also get to learn about the latest developments in the industry. The reason is that these products or services have the potential to disrupt this line of business. If there is information about company acquisitions or mergers, this information will also be available in this portion of the Direct-to-Consumer Genetic Testing (DTC-GT) Market report.

If you have any special requirements about this Direct-to-Consumer Genetic Testing (DTC-GT) Market report, please let us know and we can provide custom report.

Inquire more about this report @ https://www.reportsandmarkets.com/enquiry/direct-to-consumer-genetic-testing-dtc-gt-global-market-status-and-trend-report-2013-2023?utm_source=jewishlifenews&utm_medium=38

About Us

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serve our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Originally posted here:
Impact of COVID-19 on Direct-to-Consumer Genetic Testing (DTC-GT) 2020 by Industry Analysis, Growth Opportunity, Future and Forecast to 2026 - Jewish...

Recommendation and review posted by Bethany Smith

The global Predictive Genetic Testing market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Predictive Genetic Testing market player in a comprehensive way. Further, the Predictive Genetic Testing market report emphasizes the adoption pattern of the Predictive Genetic Testing across various industries.

The Predictive Genetic Testing market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/31204

key players in the predictive genetic testing market. The significant competitive strength of the existing players in the evolving landscape of the global predictive genetic testing market is anticipated to offer new prospect in widening the application of the predictive genetic testing, substantially driving predictive genetic testing market growth. The key manufacturers of the predictive genetic testing are greatly concentrated on the technical edification of the end users to improve consumer outcomes. Furthermore, the adoptions of advanced predictive genetic testing services is expected to create lucrative growth opportunities for the service and third-party market competitors. Growing inclination toward trend in predict is prevention is estimated to offer growth opportunity for Predictive genetic testing market. Selection of treatment regimen with Predictive genetic testing is projected to aid capturing higher share in Predictive genetic testing market.

Geographically, global Predictive genetic testing market is segmented into seven key regions viz. North America, Latin America, Europe, South Asia, East Asia Oceania and Middle East & Africa. North America is prominent region in Predictive genetic testing Market. Advancement in genetic care facilities, higher adoption to lifestyle changes, increase awareness about genetic disease, increase in preventative care and favorable government policies have improved the regulatory scenario for predictive genetic testing devices in north America. Additionally in Asia pacific region considerably higher market growth rate is expected due to constantly rising population and higher incidence of genetic abnormality. Relatively affecting the Predictive genetic testing market.

Some of the major key players competing in the global Predictive genetic testing Market are Myriad Genetics, Inc., Abbott Laboratories, Illumina, Inc., Genesis GeneticsThermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., , Agilent Technologies, F. Hoffmann-La Roche Ltd., Counsyl, Inc., ARUP Laboratories. BGI among others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Buy the report at a discounted rate!!! Exclusive offer!!!

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/31204

The Predictive Genetic Testing market report offers a plethora of insights which include:

The Predictive Genetic Testing market report answers important questions which include:

The Predictive Genetic Testing market report considers the following years to predict the market growth:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/31204

Why Choose Predictive Genetic Testing Market Report?

Predictive Genetic Testing Market Reportfollows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

See the article here:
Predictive Genetic Testing Market Report 2019: With Essential Analysis of Market, Industry News and Policies by Regions, Top Manufacturers, Types and...

Recommendation and review posted by Bethany Smith

Genetic Testing Market has witnessed continuous growth within the past few years and is projected to grow even more throughout the forecast period (2020 2027). The analysis presents a whole assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical information, and statistically supported and trade valid market information.

The report, titled Global Genetic Testing Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

You Can Request A Demo Version of Report Before Buying (Higher Preference For Corporate Email ID User): https://www.worldwidemarketreports.com/sample/307245

GeneDx, Invitae, Pathway Genomics, Counsyl Inc, Asper Biotech, GenePlanet, Courtagen Life Sciences, Gene By Gene, Natera Inc, Regulatory, GeneTests, United Gene, HI Gene, Berry Genomics, 23andMe Inc, 360Jiyin, Novogene, CapitalBio, Agen, Biomedlab, Biomarker, Annoroad, Aiyin Gene, Aijiyin, Repconex, Find Bio-Tech, SinoGenoMax, Gene Kang, Geeppine, BGI of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

1. Industry outlookThis is where youll find the current state of the Genetic Testing industry overall and where its headed. Relevant industry metrics like size, trends, life cycle, and projected growth included here. This report comes prepared with the data to back up your business idea. On a regional basis, the Global Genetic Testing market has been segmented into Asia-Pacific, North America, Europe, Latin America, and the Middle East and Africa.

2. Target marketThis target market section of study includes the following:

User persona and characteristics: It includes demographics such as age, income, and location. It lets you know what their interests and buying habits are, as well as explain the best position to meet their needs.

Market size: How big is the potential Genetic Testing market for your business? It brings to light the consumption in the Genetic Testing industry by the type and application.

3. Competitive analysisDiscover your competitors. The report lets you know what youre up against, but it also lets you spot the competitions weaknesses. Are there customers that are underserved? What can you offer that similar businesses arent offering? The competitive analysis contains the following components:

Direct competitors: What other companies are offering similar products and services? Which companies are your true competitors?

Competitor strengths and weaknesses: What is your competition good at? Where do they fall behind? Get insights to spot opportunities to excel where others are falling short.

Barriers to entry: What are the potential pitfalls of entering the Genetic Testing market? Whats the cost of entry? Is it prohibitively high, or easy to enter?

The window of opportunity:Does your entry into the Genetic Testing industry rely on time-sensitive technology? Do you need to enter early to take advantage of an emerging market?

4. ProjectionsLikewise, We offered thoughtful, not hockey-stick forecasting.

Market share:We have given the consumption behavior of users. When you know how much can your future customers spend, then only youll understand how much of the Genetic Testing industry you have a chance to grab, and here we came up with real stats and numbers.

Impact Analysis of COVID-19:The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into account the political, economic, social, and technological parameters.

Finally, It is one report that hasnt shied away from taking a critical look at the current status and future outlook for the consumption/sales of these products, by the end users and applications. Not forgetting the market share control and growth rate of the Genetic Testing Industry, per application. Most noteworthy, this market analysis will help you find market blind spots.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

View original post here:
COVID-19 Impact on Genetic Testing Market Down to a Trickle Month Other Traders Cling on the Hope: GeneDx, Invitae, Pathway Genomics - Daily Research...

Recommendation and review posted by Bethany Smith

Predictive Genetic Testing And Consumer/Wellness Genomics Marketreport focused on the comprehensive analysis of current and future prospects of the Predictive Genetic Testing And Consumer/Wellness Genomics industry. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and micro environmental factors. An in-depth analysis of past trends, future trends, demographics, technological advancements, and regulatory requirements for the Predictive Genetic Testing And Consumer/Wellness Genomics market has been done in order to calculate the growth rates for each segment and sub-segments.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report:

https://www.a2zmarketresearch.com/sample?reportId=115261

Top Key Vendors of this Market are:

Illumina, BGI, Genesis Genetics, Myriad Genetics, 23andMe, Inc, Color Genomics Inc, Pathway Genomics, ARUP Laboratories.

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Predictive Genetic Testing And Consumer/Wellness Genomics market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Predictive Genetic Testing And Consumer/Wellness Genomics markets trajectory between forecast periods.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Predictive Genetic Testing And Consumer/Wellness Genomics market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Predictive Genetic Testing And Consumer/Wellness Genomics market.

Hurry Up! To Get Upto 25% on this Report:

https://www.a2zmarketresearch.com/discount?reportId=115261

The report summarized the high revenue that has been generated across locations like, North America, Japan, Europe, Asia, and India along with the facts and figures of Predictive Genetic Testing And Consumer/Wellness Genomics market. It focuses on the major points, which are necessary to make positive impacts on the market policies, international transactions, speculation, and supply demand in the global market.

Reasons for buying this report:

Table of Contents

Global Predictive Genetic Testing And Consumer/Wellness Genomics Market Research Report 2020 2026

Chapter 1 Predictive Genetic Testing And Consumer/Wellness Genomics Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Predictive Genetic Testing And Consumer/Wellness Genomics Market Forecast

For Direct Purchase, Visit @:

https://www.a2zmarketresearch.com/buy?reportId=115261

If you have any special requirements, please let us know and we will offer you the report as you want.

Visit link:
Predictive Genetic Testing And Consumer/Wellness Genomics Market to Witness Explosive Rise by 2026 with Top Key Players like Illumina, BGI, Genesis...

Recommendation and review posted by Bethany Smith

Newswise Massachusetts Eye and Ear, a member hospital of Mass General Brigham, is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common causes for autosomal dominant retinitis pigmentosa.

Inherited retinal degenerations (IRDs), such as retinitis pigmentosa, are a group of blinding eye diseases caused by mutations in over 270 different genes. Mutations in the PRPF31 gene are the second most common cause of dominant IRD and lead to defects in the function of the retinal pigment epithelial (RPE) cells and photoreceptors of the retina. Previous lab-based research performed by members of the Ocular Genomics Institute at Harvard Ophthalmology, led by Eric A. Pierce, MD, PhD, demonstrated that adeno-associated virus (AAV)-mediated gene augmentation therapy for PRPF31 can restore normal function to PRPF31 mutant RPE cells.

Biogen (Nasdaq: BIIB), a biopharmaceutical company that discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies, will build upon this prior work, and conduct the studies needed for clinical development of PRPF31 gene therapy. This includes the pre-clinical studies needed to support progression to clinical trials of PRPF31 gene therapy. As part of the agreement, Biogen will receive an exclusive license to develop the product worldwide and will be responsible for all U.S. Food and Drug-Administration (FDA) required investigational new drug (IND) enabling studies, clinical development and commercialization.

The treatment of IRDs with highly effective AAV-based gene therapies is core to Biogens ophthalmology strategy, said Chris Henderson, Head of Research, Biogen. This agreement underscores our commitment to that strategy and builds off of our acquisition of Nightstar Therapeutics in 2019 and our active clinical trials of gene therapies for different genetic forms of IRD. We are excited to work with Massachusetts Eye and Ear and look forward to applying our preclinical and clinical experience to their leading PRPF31 program.

We are thrilled to work with Biogen, who will bring to this effort its deep experience with the clinical development process, as we work toward our goal of developing a gene therapy for people with PRPF31-related eye disease, added Dr. Pierce, who is the William F. Chatlos Professor of Ophthalmology at Harvard Medical School. My ultimate hope for patients with inherited retinal disorders due to mutations in PRPF31 is that a gene therapy will preserve and potentially restore some of their vision.

About the Ocular Genomics Institute

The Ocular Genomics Institute at Harvard Ophthalmology aims to translate genomic medicine into precision ophthalmic care for patients with inherited eye disorders. It is home to one of the leading centers for early-phase clinical trials of therapies for inherited retinal degenerations, with seven gene-based and one stem cell trial currently in progress. The group works in conjunction with other departments throughout Harvard Medical School and Mass. Eye and Ear, including the Bioinformatics Center and Grousbeck Gene Therapy Center.

Dr. Pierces lab, established in 2011, is dedicated to research in an effort to improve the understanding of the molecular bases of IRDs so that rational therapies can be developed for these diseases.

In 2018, Mass. Eye and Ear surgeons performed the first post-FDA approval gene therapy for patients with a form of inherited retinal blindness caused by mutations in the gene RPE65 by injecting an AAV-based drug treatment into a patients eye, which restored vision in a 13-year-old boy. This therapy, called Luxturna, is now being used to treat patients with RPE65-associated retinal degeneration around the world.

One of the exciting aspects of our collaboration with Biogen is that mutations in the PRPF31 gene affect approximately 10 to 20 times more people than mutations in the RPE65 gene, said Dr. Pierce. Success with PRPF31 gene therapy could provide visual benefit to more patients, which is our ultimate goal.

Mass. Eye and Ear was one of the first centers to offer life-changing gene therapies to patients with inherited retinal disease, and we are thrilled with this new opportunity to develop a translational retinal therapy that could help even more patients, said Joan W. Miller, MD, Chief of Ophthalmology at Mass. Eye and Ear, Massachusetts General Hospital, and Brigham and Womens Hospital, and Chair of Ophthalmology and the David Glendenning Cogan Professor of Ophthalmology at Harvard Medical School.

According to Chris Coburn, Chief Innovation Officer, Mass General Brigham, the collaboration with Biogen illustrates the importance of academia and industry teaming to solve problems for patients worldwide. We are eager to see this progress reach patients who are challenged by blinding, degenerative eye disease, said Coburn. We look forward to working with Biogen to advance this break-through innovation.

Patients with an inherited retinal disease require genetic testing prior to being considered for any gene therapy treatment.

About Massachusetts Eye and Ear

Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of Mass General Brigham, Mass. Eye and Ear specializes in ophthalmology (eye care) and otolaryngologyhead and neck surgery (ear, nose and throat care). Mass. Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass. Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 20192020 Best Hospitals Survey,U.S. News & World Reportranked Mass. Eye and Ear #4 in the nation for eye care and #2 for ear, nose and throat care.For more information about life-changing care and research at Mass. Eye and Ear, visit our blog,Focus, and follow us onInstagram,TwitterandFacebook.

About Harvard Medical School Department of Ophthalmology

The Harvard Medical SchoolDepartment of Ophthalmologyis one of the leading and largest academic departments of ophthalmology in the nation. Composed of nine affiliates (Massachusetts Eye and Ear, which is home to Schepens Eye Research Institute; Massachusetts General Hospital; Brigham and Womens Hospital; Boston Childrens Hospital; Beth Israel Deaconess Medical Center; Joslin Diabetes Center/Beetham Eye Institute; Veterans Affairs Boston Healthcare System; Veterans Affairs Maine Healthcare System; and Cambridge Health Alliance) and several international partners, the department draws upon the resources of a global team to pursue a singular goaleradicate blinding diseases so that all children born today will see throughout their lifetimes. Formally established in 1871, the department is committed to its three-fold mission of providing premier clinical care, conducting transformational research, and providing world-class training for tomorrows leaders in ophthalmology.

See more here:
Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise

Recommendation and review posted by Bethany Smith

The Esoteric Testing Market report upholds the future market predictions related to Esoteric Testing market size, revenue, production, Consumption, gross margin and other substantial factors. It also examines the role of the prominent Esoteric Testing market players involved in the industry including their corporate overview. While emphasizing the key driving factors for Esoteric Testing market, the report also offers a full study of the future trends and developments of the market.

In the report the esoteric testing market, the market is expected to reach US$ $ 45,081.6 Mn in 2025 from US$ 19,868.2 in 2017. The market is estimated to grow with a CAGR of 11.7% from 2018-2025.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/13610

The test type segment of the esoteric testing market includes infectious diseases testing, oncology testing, genetic testing, neurology testing, endocrinology testing, toxicology testing and others. The test type segment for the esoteric testing market was valued at US$ 19,868.2 Mn in 2017 and is estimated to reach US$ 45,081.6 Mn by 2025. The infectious diseases testing segments is likely to dominate the market in the coming future owing to large number of infectious disease tests that are performed in clinical laboratories, technological innovations in molecular diagnostics and increasing healthcare infrastructure in developing nations. The endocrinology testing segments are the fastest growing segment in the test type and is expected to be the fastest growing segment in the forecast period owing to the increase in the number of the endocrinology tests.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/13610

The esoteric testing market is driven by the driving factor such as rising prevalence of infectious diseases, growing awareness regarding early detection using specific diagnostics tests and increasing geriatric population & associated growth in chronic diseases. The market is likely to restrain its growth due to the factors such as lack of skilled professionals and poor reimbursement scenarios for the esoteric testing. Whereas the trend of utilizing the technologies in esoteric testing for various applications are likely to propel the growth of the market.

What will you get in this report?

The esoteric testing market as per the technology the segment is segmented as chemiluminescence immunoassay, real-time PCR, flow cytometry, mass spectrometry, enzyme-linked immunosorbent assay and others. The market of chemiluminescence immunoassay has the highest market share in 2017, contributing a market share of 25.2% and is expected to retain its dominance during the forecast period from 2018 to 2025. The higher acceptance of the chemiluminescence immunoassay for the esoteric testing are due to the advantages for the analytical procedures likely to propel the esoteric testing market in the coming future. Similarly, the enzyme-linked immunosorbent assay contributed 21.1% of the market share in the year 2017 and is expected to be the fastest growing market in the coming forecast period.

Some of the major primary and secondary sources included in the report esoteric testing market are International Diabetes Federation, Laboratory Corporation of America Holdings Diagnostics, Ministry of Health, South Africa Regional Global Disease Detection Centre, Centers for Disease Control and Prevention, National Department of Health, National Health Laboratory Service, Dubai Health Authority, Dubai Healthcare City, Joint Advisory Group, New Rural Cooperative Medical System and more.

Some of the Highlights about Table of Content of Esoteric Testing Market

1 Esoteric Testing Market overview

2 Executive Summary

3 Market Drivers, Challenges and Trends

4 Marketing, Distributors and Customer

5 Key Players Analysis

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/13610

See the article here:
Esoteric Testing Market Analysis, Competitive Strategies and Forecasts to 2025 - CueReport

Recommendation and review posted by Bethany Smith

Bone marrow aspiration and trephine biopsy are usually performed on the back of the hipbone, or posterior iliac crest. An aspirate can also be obtained from the sternum (breastbone). For the sternal aspirate, the patient lies on their back, with a pillow under the shoulder to raise the chest. A trephine biopsy should never be performed on the sternum, due to the risk of injury to blood vessels, lungs or the heart.

Get Access to sample pages:https://www.trendsmarketresearch.com/report/sample/3374

The need to selectively isolate and concentrate selective cells, such as mononuclear cells, allogeneic cancer cells, T cells and others, is driving the market. Over 30,000 bone marrow transplants occur every year. The explosive growth of stem cells therapies represents the largest growth opportunity for bone marrow processing systems.

Europe and North America spearheaded the market as of 2018, by contributing over 74.0% to the overall revenue. Majority of stem cell transplants are conducted in Europe, and it is one of the major factors contributing to the lucrative share in the cell harvesting system market.

In 2018, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.

Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy. Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and increase in aging population can be attributed to the increasing demand for these therapies in these countries.

Major players operating in the global bone marrow processing systems market are ThermoGenesis (Cesca Therapeutics inc.), RegenMed Systems Inc., MK Alliance Inc., Fresenius Kabi AG, Harvest Technologies (Terumo BCT), Arthrex, Inc. and others..

COVID-19 Impact Analysis@https://www.trendsmarketresearch.com/report/covid-19-analysis/3374

More:
Bone Marrow Processing Systems Market Expansion Projected to Gain an Uptick during COVID-19 Crisis 2018 2025 - Kentucky Journal 24

Recommendation and review posted by Bethany Smith

Stem Cell Therapy Market Insights 2020

Increasing Awareness Related to the Stem Cells Therapy in Effective Disease Management

Stem cell research has been widely investigated globally to enhance human health in a medical setting. For this, creating public awareness about stem cell research is vital for realizing this potential. The stem cells main role is to replace dying cells and reconstruct damaged tissues. Based on the extensive stem cell research results, many scientists have claimed that the cells could probably generate cures and treatment for various diseases, including cancers, cardiovascular disease, and others. Newly developed stem cell therapies having the capability to replace disease, causing cells. Hence, patients now started relying on stem cell therapy that has long term positive outcomes. There is an increasing number of potential treatments that are undergoing in clinical trials phase. The FDA has approved very few stem cell therapies. For instance, in 2019, Fedratinib, approved by the FDA for the first-line treatment for fibrosis. Bone marrow transplantation is widely used stem cell based therapy. Blood forming stem cells were the first to be used in the clinic. This stem cell therapy has benefited thousands of patients who have leukemia.

Download sample PDF copy at:https://www.theinsightpartners.com/sample/TIPHE100000991/

Strategic Insights

Product launches and FDA approvals strategy is commonly adopted by companies to expand their footprint worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in order to expand its product portfolio.

The market players operating in the stem cell therapy market adopt the strategy of collaborations to enlarge customer base across the world, which also permits the players to maintain their brand name globally.

Company Profiles

The stem cell therapy market is expected to grow, owing to factors such Increasing awareness related to the stem cells therapy in effective disease management, growing demand for regenerative medicines, and growing cancer prevalence across the globe are likely to have a positive impact on the growth of the market in coming years.

Purchase Copy of This Report at: https://www.theinsightpartners.com/buy/TIPHE100000991/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact Us:

Call: +1-646-491-9876

Email: [emailprotected]

Visit link:
Stem Cell Therapy Market to 2027 Global Analysis and Forecast by Type, Treatment, End User - Apsters News

Recommendation and review posted by Bethany Smith

A recent report published by QMI on mesenchymal stem cells market is a detailed assessment of the most important market dynamics. After carrying out a thorough research of mesenchymal stem cells market historical as well as current growth parameters, business expectations for growth are obtained with utmost precision. The study identifies specific and important factors affecting the market for mesenchymal stem cells during the forecast period. It can enable manufacturers of mesenchymal stem cells to change their production and marketing strategies in order to envisage maximum growth.

Get Sample Copy of This Report @https://www.quincemarketinsights.com/request-sample-61514?utm_source=3WN&utm_medium=santosh

According to the report, the mesenchymal stem cells market has been segmented by source (bone marrow, umbilical cord blood, peripheral blood, lung tissue, synovial tissues, amniotic fluids, adipose tissues), by application (injuries, drug discovery, cardiovascular infraction, others).Insights about the regional distribution of market:The market has been segmented in major regions to understand the global development and demand patterns of this market.

For the mesenchymal stem cells market, the segments by region are North America, Asia Pacific, Western Europe, Eastern Europe, Middle East, and Rest of the World. During the forecast period, North America, Asia Pacific and Western Europe are expected to be major regions on the mesenchymal stem cells market.

North America and Western Europe have been one of the key regions as they have an established healthcare infrastructure for product innovations and early adaptations. This is estimated to drive demand for the mesenchymal stem cells market in these regions. In addition to this, some of the major companies operating in this market are headquartered in these regions.

Asia Pacific is estimated to register a high CAGR mesenchymal stem cells market. The APAC region has witnessed strategic investments by global companies to cater to the growing demand for healthcare solutions in recent years. The Middle East and Rest of the World are estimated to be emerging regions for the mesenchymal stem cells market.

Make An Inquiry For Purchasing This Report @https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-61514?utm_source=3WN&utm_medium=santosh

Market Players Cell Applications, Inc., Cyagen Biosciences Inc. Axol Bioscience Ltd., Cytori Therapeutics Inc., Stem Cell Technologies Inc., Celprogen, Inc.

Reasons to Buy This Report:o It provides niche insights for a decision about every possible segment helping in the strategic decision-making process.o Market size estimation of the mesenchymal stem cells market on a regional and global basis.

o A unique research design for market size estimation and forecast.o Identification of major companies operating in the market with related developmentso Exhaustive scope to cover all the possible segments helping every stakeholder in the mesenchymal stem cells market.

Market Segmentation:By Source:o Bone Marrowo Umbilical Cord Bloodo Peripheral Bloodo Lung Tissueo Synovial Tissueso Amniotic Fluidso Adipose Tissues

By Application:o Injurieso Drug Discoveryo Cardiovascular Infractiono Others

By Region:o North Americao North America, by Country? US? Canada? Mexicoo North America, by Sourceo North America, by Application

o Western Europeo Western Europe, by Country? Germany? UK? France? Italy? Spain? The Netherlands? Rest of Western Europeo Western Europe, by Sourceo Western Europe, by Application

o Asia Pacifico Asia Pacific, by Country? China? India? Japan? South Korea? Australia? Indonesia? Rest of Asia Pacifico Asia Pacific, by Sourceo Asia Pacific, by Application

o Eastern Europeo Eastern Europe, by Country? Russia? Turkey? Rest of Eastern Europeo Eastern Europe, by Sourceo Eastern Europe, by Application

o Middle Easto Middle East, by Country? UAE? Saudi Arabia? Qatar? Iran? Rest of Middle Easto Middle East, by Sourceo Middle East, by Applicationo Rest of the Worldo Rest of the World, by Country? South America? Africao Rest of the World, by Sourceo Rest of the World, by Application

Years Covered in the Study:Historic Year: 2016-2017Base Year: 2018Estimated Year: 2019Forecast Year: 2028

Objectives of this report:o To estimate the market size for mesenchymal stem cells market on a regional and global basis.o To identify major segments in mesenchymal stem cells market and evaluate their market shares and demand.

o To provide a competitive scenario for the mesenchymal stem cells market with major developments observed by key companies in the historic years.o To evaluate key factors governing the dynamics of mesenchymal stem cells market with their potential gravity during the forecast period.Customization:This study is customized to meet your specific requirements:

o By Segmento By Sub-segmento By Region/Countryo Product Specific Competitive Analysis

Contact:Quince Market InsightsAjay D. (Knowledge Partner)Office No- A109Pune, Maharashtra 411028Phone: +91 706 672 4848 +1 208 405 2835 / +44 121 364 6144 /Email: [emailprotected]Web:www.quincemarketinsights.com

ABOUT US:QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Read more:
Impacts of the COVID-19-Mesenchymal Stem Cells Market Size Current and Future Industry Trends, 2020-2028 - 3rd Watch News

Recommendation and review posted by Bethany Smith

Spending extra time indoors (and separated from our typical grooming resources) has shifted our focus to the few aesthetic things we can control, like doubling down on our skin care routine.

Perhaps thats why Marissa Collections has seen an increase in demand for Vintners Daughter, a beauty line founded by Naples native and third-generation winemaker April Gargiulo. During times of stress, self-care is the one thing people can do for themselves to give that balance, since they cant go to a hair salon or their favorite shop, says Laura Pangallo, Marissa Collections jewelry and beauty sales manager.

Vintners Daughter has experienced a meteoric rise since it launched in 2013, as one of the pioneering names in the clean-beauty movementa shift away from using chemical-ridden products and toward embracing simpler, plant-based skin care routines.

Marissa Collections started carrying the line three years ago, when Pangallo began noticing an uptick of natural skin care brands entering the market. With its local connection, Vintners Daughter was a natural fit for Naples. Garguilo, whose parents still live here part-time and are trustees of the Naples Children & Education Foundation, grew up with the shops CEO, Jay Hartington. Many members of the team also use the products and attest to their effectiveness. One thing thats unique is that Vintners Daughter doesnt have 20 or 30 products; they have two, and they make them well, and they really work, Pangallo says. Im a skin care junkie, and when I started using the essence, I instantly noticed the difference.

Gargiulo has been called the sommelier of skin care and her award-winning seruma face oil infused with 22 nutrient-rich botanicals, including skin-firming cypress from Spain and pore-shrinking hazelnut from Piedmontis what she considers to be her desert island, holy grail skin product.

Eight years ago, when Gargiulo was pregnant with her first daughter and working with her familys eponymous winery in California, she started examining the labels of the luxury products she was slathering on her face. She was shocked that only 0.01% of what was in the bottles contained active ingredients (those that address the targeted issue)the rest were filler. For me, luxury was far more than a price tag, and the only thing luxurious about these products was the price, she says.

At the time, face oils hadnt become mainstream and the 10-step Korean skin care routine was still popular. I thought if you were using natural, you had to compromise, she admits. She was eager to keep her body and family clear from toxins, but none of the chemical-free products she found were powerful enough to address her lifelong struggle with acne and discoloration and the onset of wrinkles she started to experience in her 30s.

Working with a seasoned formulator, Gargiulo spent the next two years developing the formula for her liquid gold serum. It would be another four years before shed release a second product, the Active Treatment Essence, which launched last year.

Labs she met with initially, when she was developing the serum, turned her away. They were put off by her proposition for a beauty product that would take three weeks (instead of the standard six hours) to produce. Im coming from winemaking, where youre thinking of the grapes and where theyre grown, and it takes three years to make a bottle of wine, she says. I thought three weeks was nothing. Another hitch? Instead of relying on the usual mix of chemicals and extracts, her formula required whole plantsall sourced from growers with generations of experience.

Napa Valleys winemaking culture motivated her to push onward when she was rejected by labs and retailers. Over the past 60 to 70 years, really audacious men and women put Napa Valley on the map for the finest wines in the world, and the passion it took is something that I still look to for inspiration, Gargiulo says.

The launch presented a revelation for the beauty industry. With no marketing dollars spent, editors, celebs and name-brand aestheticians flocked to this brand that had a singular product, doled out in tiny, unassuming, matte black bottles, retailing for $185. Whether they were looking to tackle pore size or reduce fine lines, early adopters found the serum actually worked across generations, skin types and for various issues.

Every dimension of the productfrom the tiny particle size, which allows the serum to better penetrate the skin, to the ratios usedis thought out to effectively target skin concerns. The serum still takes three weeks to make, a process that includes extracting every nutrient the plant has to offer.

Gargiulo took her time in developing the brands second product. The essencea primer applied to clean skin to boost hydration and the serums other effectstakes five weeks to make. The ingredients are fermented for better absorption and to deliver antioxidant-rich prebiotics and probiotics. Added plant stem cells and hyaluronic acid help the skin produce more collagen and hydrate at the deepest level.

For now, the 45-year-old skin care guru is perfectly happy selling the two products, which combine for a two-step process that promises to brighten, tighten and protect skin. The prescription? Pat on the essence, then press a few drops of the serum onto your skin, followed by sunscreen during the day.

At the beginning of the coronavirus outbreak, like so many of us, Gargiulo turned to her beauty products as a way to de-stress. She was loading up on masks and applying products multiple times a day, only to find her acne-prone skin flared up. The experience nudged her back to her baseline. I was like, April, what are you thinking? You know better, she says. After years of winemaking, she knows that higher quality and a smaller yield always offers you better results.

Visit link:
Seed to Skin - Gulfshore Life

Recommendation and review posted by Bethany Smith

Jul 4th 2020

Editors note: Each of these climate-change articles is fiction, but grounded in historical fact and real science. The year, concentration of carbon dioxide and average temperature rise (above pre-industrial average) are shown for each one. The scenarios do not present a unified narrative but are set in different worlds, with a range of climate sensitivities, on different emissions pathways

IN THE LATE 1980s Michael Crichton, a novelist and filmmaker, had a lucrative idea. He picked up on the work of Allan Wilson, a geneticist at the University of California, Berkeley, and let his imagination run riot. Wilson had extracted DNA from an extinct type of zebra called a quagga. The DNA in question was fragmented, and the extinction of the quagga only a century in the past, but that did not matter. Crichton speculated about recovering far older DNA than the quaggas by looking in the guts of bloodsucking insects preserved in amber that had formed millions of years ago, during the age of the dinosaurs. If the insects had been feasting on dinosaurs, he mused, they might have preserved those creatures DNA. And if you have somethings DNA you could, perhaps, recreate it. The result was Jurassic Park.

Sadly, there is no sign of any real DNA having been preserved from that far back in the past. But be a bit less ambitious in your time-travelling, and apply the three decades worth of biotechnological advances that have happened since Jurassic Park was published to the question of how you might go forward from here, and the aspiration of recreating at least some prehistoric creatures no longer seems completely fanciful. It may, moreover, be of practical importance, because one animal the de-extinctionists have in their sights is the woolly mammoth. And some people believe that reintroducing mammoths into the wild would make a change to the ecology of Earths northern reaches sufficiently large as to help curb global warming.

This, then, is the idea behind the Harvard Woolly Mammoth Revival Project, run by George Church. Unlike the long-dead dinosaurs in Jurassic Park, mammoths were present on Earth as recently as 4,000 years ago. That, and the fact that many of the parts of the world in which they lived are still pretty chilly, means quite a lot of mammoth DNA remains reasonably intact in frozen corpses recovered from the tundraenough for palaeogeneticists to have reconstructed the animals genome. And with a genome, as Crichton mused, you can aspire to produce an animal.

Mammoths are a species of elephant. This helps because two (or, according to some taxonomists, three) other species of these animals remain alive today to provide assistance to the mammoth-revivers. Though African elephants (one species, or possibly two) are closer in size to mammoths than their Asian cousins are, genetics show that the Asian variety are mammoths closest living relatives, so it is they that are the focus of Dr Churchs research.

People once fantasised about cloning a mammoth directly, from cells or cell nuclei somehow revived from a fossil specimen. Dr Churchs approach is less ambitious and more realistic. It is to engineer the crucial elements of mammothness into Asian-elephant cells and then use these modified cells to create beasts which have the characteristics of mammoths, even if they are not strictly the real thing.

The technology that may make this possible is CRISPR-Cas9 gene editing, which permits precise changes to be made at particular places in an existing genome. In the case of mammoths the task does not, at first sight, seem too hard. An Asian elephants genome is 99.96% similar to a mammoths. Unfortunately, the 0.04% of difference amounts to about 1.4m places in the genome where the genetic letters of the DNA message differ between the species. Most of these differences are, admittedly, in places where they probably do not matter. But there are 2,020 exceptions which, collectively, change the nature of 1,642 genesabout 6.5% of the total. It is these differences that make mammoths and Asian elephants distinct.

Dr Churchs team are therefore concentrating on mammothising what they perceive to be the most pertinent of these genomic locations. They are tweaking the genes of laboratory-grown Asian-elephant skin cells one at a time, focusing on changes they hope will promote mammoths famed hairiness, their propensity to store layers of fat beneath their skin, their cold-adapted haemoglobin and even the protein molecules in their cell membranes that act as channels for the passage of sodium ions, and which are also adapted to the cold. Whether they also tinker with genes for size is, for now at least, undecided.

The teams hope, once enough mammothness has been engendered into these cells, is that they can then be induced, by what is now a well-established laboratory procedure, to turn from being skin cells into stem cells. A stem cell is one that has the developmental plasticity needed to give rise to all sorts of other cells as it multiplies. In the short term, this approach will let Dr Church and his colleagues grow tissues such as blood, for further study. In the longer term, perhaps using an artificial womb, a stem cell of this sort might be grown into an embryo that can be brought to term. Not quite a true mammoth. But not a bad imitation.

That is all a huge technical challenge. But it is not completely fanciful. And success would usher in the second part of the plan: to liberate groups of newly created mammothoids into the wild, and let them multiply and change the Earth. This is the long-held dream of another group of researchers, led by Sergey Zimov, who runs the Russian Academy of Sciences Northeast Scientific Station, near Cherskii. Not only is it an attractive idea in its own rightfor who could resist the idea of mammoths once again thundering over Siberia?but it might also alter the climate for the better.

Dr Zimovs plan is a grand project of biogeoengineering. Recreated mammoths are the boldest part of his aspiration to revive the grassland-steppe ecosystem that dominated Siberia until the arrival there of human beings, about 30,000 years ago. It had more or less disappeared by about 10,000 years ago, the end of the Pleistocene epoch, to be replaced by the modern tundra, which is dominated by moss and small trees.

This shift in vegetation was, Dr Zimov and his colleagues believe, a result of the extinction or near-extinction at that time of most of the areas large herbivore species. This was almost certainly a consequence of hunting by human beings. Where once there were woolly rhinoceros, musk ox, bison, saiga, yaks, wild horses and mammoths, there now remain only reindeer and elk. The hooves of those vast herds of herbivores were, he believes, the crucial factor stopping the spread of moss at the expense of grass. And the crashing bulk and appetites of the largest speciesmammoths in particularwould have dealt with young trees before they could grow up, as is still the case for elephants in what remains of Africas savannah. The loss of the grassland, climate modelling suggests, propelled an increase in temperature.

One factor driving this change was that forest and moss are darker than grassland. Their spread has therefore increased the amount of sunlight absorbed by the area they are growing in, causing warming.

A second factor was that large animals helped maintain the soil in the perpetually frozen state known as permafrost, by churning up the winter snowfall and thus bringing the soil into contact with the freezing winter air. But without them, the snow instead forms an insulating blanket that allows the soil beneath to warm up. And when permafrost melts, the organic matter in it breaks down, releasing methane and carbon dioxideboth greenhouse gases.

The third pertinent effect is that grass sequesters carbon in the soil in its roots. In Arctic habitats it would do this better than the small, sparse trees now present, and much better than moss, a type of plant that has no roots. Carbon stored this way is thus kept out of the atmosphere where, in the form of carbon dioxide, it would contribute to global warming. When the grass disappeared, the storage capacity did, too.

All these things point to the idea that restoring the Siberian grasslands at the expense of the tundra would be a good thing to do. And Dr Zimov has indeed made a start at doing so, in an area of tundra, covering 160 square kilometres (62 square miles), near his research station. In 1988 he enclosed part of this area and has gradually populated it with reindeer, Yakutian horses, elk, bison, musk ox, yaks, Kalmykian cows and sheep. These coexist with several species of predator, including lynx, wolverines and brown bears. He calls this rewilding project Pleistocene Park, and thinks it would benefit greatly from having a few mammoths, or even mammoth substitutes, in it as well.

Pleistocene Park is an experiment, but it seems to be working. Grasses now dominate large parts of it, carbon storage in the soil is going up and the rate of nutrient turnover is increasing, too. This last point is important because a faster turnover of nutrients means more animals can be supported by a given areaa prerequisite for re-establishing large herds.

Clearly, for Dr Zimovs project to have any effect on the climate it would have to be carried out on a grand scale. The Northeast Siberian coastal tundra, to give the area of habitat in which Pleistocene Park is located its proper name, covers about 850,000 square kilometres, so the park is, at the moment, a mere pinprick. It would also take many decades, even without the complication of introducing as-yet-imaginary mammothoids into the mix.

Expansive though the tundra is, however, whether that effect will be large enough to weigh in the scales of a planet-sized problem is a matter of debate. The models suggest that the global temperature rise brought about by the shift from steppe to tundra was a bit over 0.1C. Reversing this shift would, presumably, push the temperature down by a similar amount. That, as Chris Field of Stanford University, in California, who was one of the modellers, points out, would help stabilise the climate, provided global temperature rises above preindustrial levels can be kept, by other means, below 1.5-2C, the objective agreed in Paris in 2015. But if the rise were much greater than this, he thinks the permafrost would melt anywaymammoths or no.

For more coverage of climate change, register for The Climate Issue, our fortnightly newsletter, or visit our climate-change hub

This article appeared in the The World If section of the print edition under the headline "Doing the tundra quick-steppe"

Read this article:
What if mammoths are brought back from extinction? - The Economist

Recommendation and review posted by Bethany Smith

A special thank you to Kathleen Dickson and Dr. John Bergeron for pointing out that yes, indeed, there are also many women who have made and continue to make significant contributions to health. We have added their additions below, but this list is by no means complete.

From open heart surgery to child-resistant containers, prestigious awards and bombs (not that kind), Canada has a long history of Canadians whose ideas and inventions have played huge roles in defining this nations healthcare.

DNA and cancer

Nada Jabado at McGill affiliated Childrens Hospital is a pioneer in pediatric cancer and her discovery of the role of what is known as the epigenome that marks the DNA in our genes in cancer. She is a leader in innovation in Health research and recognized for her leadership in the application of discoveries to address brain tumours in children.

Insulin

Perhaps the most famous health innovation to come out of Canada, if such a thing can be measured. The arrival of insulin has saved countless lives since its creation in 1922 when Frederick Banting and Charles Best isolated and extracted insulin from the pancreas of dogs. Their Nobel Prize arrived swiftly thereafter in 1923.

Go here to see the original:
28 cool health things that started with a Canadian - Regina Leader-Post

Recommendation and review posted by Bethany Smith

Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination including a COVID-19 vaccine from Moderna Therapeutics that has advanced to clinical trials with humans.

The technology relies on inserting into cells pieces of carefully designed messenger RNA (mRNA), a strip of genetic material that human cells typically transcribe from a persons DNA in order to make useful proteins and go about their business. Problems delivering mRNA safely and intact without running afoul of the immune system have held back mRNA-based therapy, but UWMadison researchers are making tiny balls of minerals that appear to do the trick in mice.

These microparticles have pores on their surface that are on the nanometer scale that allow them to pick up and carry molecules like proteins or messenger RNA, saysWilliam Murphy, a UWMadison professor of biomedical engineering and orthopedics. They mimic something commonly seen in archaeology, when we find intact protein or DNA on a bone sample or an eggshell from thousands of years ago. The mineral components helped to stabilize those molecules for all that time.

Murphy and UWMadison collaborators used the mineral-coated microparticles (MCMs) which are 5 to 10 micrometers in diameter, about the size of a human cell in a series of experiments to deliver mRNA to cells surrounding wounds in diabetic mice. Wounds healed faster in MCM-treated mice, and cells in related experiments showed much more efficient pickup of the mRNA molecules than other delivery methods.

The researchers described their findings today in the journal Science Advances.In a healthy cell, DNA is transcribed into mRNA, and mRNA serves as the instructions the cells machinery uses to make proteins. A strip of mRNA created in a lab can be substituted into the process to tell a cell to make something new. If that something is a certain kind of antigen, a molecule that alerts the immune system to the presence of a potentially harmful virus, the mRNA has done the job of a vaccine.

The UWMadison researchers coded mRNA with instructions directing cell ribosomes to pump out a growth factor, a protein that prompts healing processes that are otherwise slow to unfold or nonexistent in the diabetic mice (and many severely diabetic people).

mRNA is short-lived in the body, though, so to deliver enough to cells typically means administering large and frequent doses in which the mRNA strands are carried by containers made of molecules called cationic polymers.

Oftentimes the cationic component is toxic. The more mRNA you deliver, the more therapeutic effect you get, but the more likely it is that youre going to see toxic effect, too. So, its a trade-off, Murphy says. What we found is when we deliver from the MCMs, we dont see that toxicity. And because MCM delivery protects the mRNA from degrading, you can get more mRNA where you want it while mitigating the toxic effects.

The new study also paired mRNA with an immune-system-inhibiting protein, to make sure the target cells didnt pick the mRNA out as a foreign object and destroy or eject it.

Successful mRNA delivery usually keeps a cell working on new instructions for about 24 hours, and the molecules they produce disperse throughout the body. Thats enough for vaccines and the antigens they produce. To keep lengthy processes like growing replacement tissue to heal skin or organs, the proteins or growth factors produced by the cells need to hang around for much longer.

What weve seen with the MCMs is, once the cells take up the mRNA and start making protein, that protein will bind right back within the MCM particle, Murphy says. Then it gets released over the course of weeks. Were basically taking something that would normally last maybe hours or even a day, and were making it last for a long time.

And because the MCMs are large enough that they dont enter the bloodstream and float away, they stay right where they are needed to keep releasing helpful therapy. In the mice, that therapeutic activity kept going for more than 20 days.

They are made of minerals similar to tooth enamel and bone, but designed to be reabsorbed by the body when theyre not useful anymore, says Murphy, whose work is supported by the Environmental Protection Agency, the National Institutes of Health and the National Science Foundation and a donation from UWMadison alums Michael and Mary Sue Shannon.

We can control their lifespan by adjusting the way theyre made, so they dissolve harmlessly when we want.

The technology behind the microparticles was patented with the help of the Wisconsin Alumni Research Foundation and is licensed to Dianomi Therapeutics, a company Murphy co-founded.

The researchers are now working on growing bone and cartilage and repairing spinal cord injuries with mRNA delivered by MCMs.

Reference: Khalil et al. (2020).Single-dose mRNA therapy via biomaterial-mediated sequestration of overexpressed proteins. Science Advances.DOI: 10.1126/sciadv.aba2422.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Go here to read the rest:
Safer and More Efficient Method To Deliver Gene Therapy - Technology Networks

Recommendation and review posted by Bethany Smith

Global Gene Therapy Market Research report 2020 provides overview including size, share, industry growth, product scope, development plans, region trends, consumptions, demand factors, types and application, and value chain structure. The Global Gene Therapy analysis is also provided for the international markets including market opportunities, investment plans, historical data, and research expert opinions.

Get Sample Copy https://www.orianresearch.com/request-sample/1529811

Development policies, investment plans, cost structures, capacity are discussed as well as growth rate, manufacturing processes, economic growth are analyzed. This Gene Therapy research report also states import/export data, industry supply and consumption figures as well as cost structure, price, industry revenue (Million USD) and gross margin by regions like (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China etc.)

The major players profiled in this report include:

Inquire more or share questions if any before the purchase on this report https://www.orianresearch.com/enquiry-before-buying/1529811

Gene Therapy Industry research report is a meticulous investigation of the current scenario of the Gene Therapy global and regional market, which covers several industry dynamics. The Gene Therapy market research report is a resource, which provides current as well as upcoming technical and financial details with market risk, growing demand and raw materials. The thorough analysis in this Gene Therapy report enables investors, CEOs, regional traders, suppliers, top vendors to understand the market in a better way and based on that knowledge make well-informed decisions.

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Gene Therapy for each application, including-Medical

Place a Direct Order of this Report https://www.orianresearch.com/checkout/1529811

Gene Therapy Market Report Table of Contents:

Chapter 1 Gene Therapy Market Executive Summary

Chapter 2 Gene Therapy Abbreviation and Acronyms

Chapter 3 Gene Therapy Preface

Chapter 4 Gene Therapy Market Landscape

Chapter 5 Gene Therapy Market Trend Analysis

Chapter 6 Gene Therapy Industry Chain Analysis

Chapter 7 Latest Gene Therapy Market Dynamics

Chapter 8 Gene Therapy Trading Analysis

Chapter 9 Historical and Current Gene Therapy in North America (2014-2019)

Chapter 10 Historical and Current Gene Therapy in South America (2014-2019)

Chapter 11 Historical and Current Gene Therapy in Asia & Pacific (2014-2019)

Chapter 12 Historical and Current Gene Therapy in Europe (2014-2019)

Chapter 13 Historical and Current Gene Therapy in MEA (2014-2019)

Chapter 14 Summary for Global Gene Therapy (2014-2019)

Chapter 15 Global Gene Therapy Forecast (2020-2024)

Chapter 16 Gene Therapy Analysis of Global Key Vendors

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

Contact Us

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (832) 380-8827 | UK: +44 0161-818-8027

Email: [emailprotected]

The rest is here:
Why Gene Therapy Market Trending in 2020? Know COVID-19 Impact on Growth and Forecast Research till 2024 - Jewish Life News

Recommendation and review posted by Bethany Smith

The latest research report on the Gene Therapy market covering in-depth analysis of size, segmentation market growth, market share, competitive Landscape, Detailed List of Key Buyers and End-Users, Market Attractiveness Analysis, and Key Investment Opportunity Analysis, product launches, area marketplace expanding, and technological innovations.

Leading market research company Facts & Factors (FnF) published a market research report onGene Therapy Market By Type (Germ Line Gene Therapy and Somatic Gene Therapy), By Vector Type (Viral Vectors, Non-Viral Vectors, and Human Artificial Chromosome), and By Therapy Area (Cancer, Neurological Diseases, Infectious Diseases, Genetic Disorders, Rheumatoid Arthritis, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 2027includes 190+ pages research PDF with TOC including a list of table and figures in its research offerings.

TheGene Therapy marketreport analyses and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire Gene Therapy market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value (USD Billion) from FY 2016 2026.

The Gene Therapy market 2020-2026 report includes market size, segmentation, growth, trends, opportunities, and challenges. The Gene Therapy market includes factors driving industry growth and opportunities. Gene Therapy market size & share report evaluates current market scenario, insights, and updates about the corresponding segments involved in the global and regional market for the forecast period of 2020-2026. The Gene Therapy market research includes historical and forecasts market data, demand, application details, price trends, and company shares of the leading Gene Therapy by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

Request an Exclusive Free Sample Report of Gene Therapy Market:https://www.fnfresearch.com/sample/gene-therapy-market-by-type-germ-line-gene

(The sample of this report is readily available on request).

Benefits of Requesting a FREE Sample Report Before Purchase:

(Note: The sample of this report is updated with COVID-19 analysis before delivery)

Some of Following Top Market Players Profile Included in This Report:

Gene Therapy Market Analysis by Leading Market Players

Leading top market players in the Gene Therapy market are analyzed in the report along with their business overview, operations, geographical locations, financial analysis, SWOT profile, and Gene Therapy products & services.

COVID-19- Current Scenario, Potential Impact, and Strategic Situation Analysis

Various communities and companies are doing their best to function and perform, and eventually cope with the challenges raised by COVID-19 pandemic. The COVID-19 pandemic had a negative impact on the market size for the year 2020, with small and medium scale companies struggling to sustain their businesses in the near term future. Industry leaders are now focusing to create new business practices to deal with crisis situations like COVID-19 pandemic.

COVID-19 is turning into a pandemic. Prepare your organization for the changes beginning to take place. Develop an understanding of the risks and probabilities and learn how your industry and your nation will be affected.

Enquire About COVID-19 Updates for This Report:https://www.fnfresearch.com/inquiry/gene-therapy-market-by-type-germ-line-gene

Report Analysis Overview:

The report includes an elaborate executive summary along with a snapshot of the growth behavior of various segments in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the Gene Therapy market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the Gene Therapy market.

The report delves into the competitive landscape of the Gene Therapy market. Key players operating in the global Gene Therapy market are identified and each one of these is profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT analysis are some of the attributes of players in the Gene Therapy market profiled in this report.

Request Customized Copy of Report @https://www.fnfresearch.com/customization/gene-therapy-market-by-type-germ-line-gene

(We customize your report according to your research need. Ask our sales team for report customization.)

Free Customization

This report includes Free Customization which generally involves a breakout of particular industries or country data at no additional charge. An analyst call can be arranged as part of this which is included in the free customization offering. The Gene Therapy Market can be customized to the country level or any other market segment. Besides this, the report understands that you may have your own business need, hence we also provide fully customized solutions to clients.

Spreadsheet Chapters include

Market Consumption in US$ by Country by Product/Service by Year. Market, Financial, Competitive, Market Segmentation, Industry, Critical Parameters, Marketing Costs, Markets, Decision Makers, Performance, Product Launch.

Read More Report Details Here:https://www.fnfresearch.com/gene-therapy-market-by-type-germ-line-gene

The Report Covers

About Us:

Facts & Factorsis a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background. Our wide-ranging database offers statistics and detailed analysis of different industries worldwide that help the clients in achieving sustainable progress. The well-organized reports help clients in developing strategies and making informed business decisions.

Contact Us:

Facts & Factors

A 2108, Sargam,

Nanded City,

Sinhagad Road,

Pune 411041, India

USA: +1-347-989-3985

E-Mail:[emailprotected]

Web:https://www.fnfresearch.com

Continued here:
Size & Trends of Gene Therapy Market Research Report 2020 Updated With COVID-19 Analysis and Forecast till 2026 - Jewish Life News

Recommendation and review posted by Bethany Smith

Biogen has picked up a new, preclinical gene therapy program from Massachusetts Eye and Ear for inherited retinal degeneration due to mutations in the PRPF31 gene, among the most common causes for autosomal dominant retinitis pigmentosa. Theyre building on the work of Harvards Eric Pierce. The treatment of IRDs with highly effective AAV-based gene therapies is core to Biogens ophthalmology strategy, said Chris Henderson, the research head at Biogen. This agreement underscores our commitment to that strategy and builds off of our acquisition of Nightstar Therapeutics in 2019 and our active clinical trials of gene therapies for different genetic forms of IRD.

Sarepta has inked a collaboration with Hansa to develop their experimental drug imlifidase as a pre-treatment for their gene therapies. The drug is intended for use in patients who have neutralizing antibodies that would prevent gene therapies for Duchenne muscular dystrophy and Limb-girdle muscular dystrophy from working. Hansa gets a $10 million upfront and up to $397.5 million in milestones.

Its been raining money on Wall Street at least when it comes to drug developers. CRISPR Therapeutics $CRSP and Acceleron each raised a whopping $450 million this week after pricing follow-on offerings. CRISPR priced 6,428,572 common shares at a public offering price of $70.00 per share, while Acceleron $XLRN auctioned off 4,864,864 shares of common stock at a price to the public of $92.50 per share.

The transatlantic biotech player Immatics has completed its flip onto Nasdaq through the Arya Sciences Acquisition Corp. The cancer drug biotech will trade as $IMTX after it raised $253 million in the process. The SPAC was set up by Perceptive Advisors.

Seattle-based Neoleukin Therapeutics, meanwhile, raised $76.2 million $NLTX for its work on protein therapeutics.

The rest is here:
Biogen bags an AAV gene therapy program from Massachusetts Eye and Ear; Biotechs raised $1B-plus in latest round of follow-ons - Endpoints News

Recommendation and review posted by Bethany Smith

Integrated Health System is bringing cell and gene therapy to cats, dogs, and horses. Recently IHS Pets has helped a paralyzed dog with a spinal cord injury to walk again after it was treated with experimental PRP and prolotherapy. Click here to see the video.

Telomeres

Aging is the root of virtually every complex noncommunicable disease in humans and animals. Telomeres are the protective end caps on the ends of our chromosomes, they are as important for the health of both humans and our pets, and they play roles in longevity.

One of the contributing factors in the lifespan in dog breeds is telomere length. As in humans researchers have found that telomere length is a strong predictor of average life span among 15 different breeds consistent with telomeres playing a role in life span determination. Dogs lose telomeric DNA ~10-fold faster than humans, which is similar to the ratio of average life spans between these species. As such telomerase therapy may be beneficial to pets as well as their human caretakers.

Telomerase gene therapy has been shown to extend lifespan in animals, this therapy may help to increase bone mineral density, improve motor performance, improve metabolism, and improve brain function.

Follistatin

The loss of muscle mass with age is just as problematic for animals as it is to humans; in cats for instance a study showed that for each 100g loss of lean body mass increased the risk of death by 20%. This is typically accompanied by frailty, and it is a contributing factor to metabolic syndrome, diabetes, heart disease, and overall mortality.

Diet and exercise have been shown to pay key roles in keeping pets healthy, but the loss of muscle mass is unavoidable without an effective intervention. Enter follistatin: myostatin blocks muscle growth, when it is inhibited then follistatin is able to let muscles grow freely to stop them from wasting away.

Follistatin gene therapy has been shown to be safe and effective in animals, this therapy may help to protect against frailty, increase muscle density, increase strength, and increase endurance.

Klotho: The Queen of Anti-Aging Proteins

1 in 3 cats will suffer from renal disease, but these numbers are under scrutiny with some suggesting that estimate may be too conservative. Chronic kidney failure can occur gradually over months or years, and it is one of the most common conditions affecting older cats with most cases progressing over time worsening the disease.

Klotho is known to play a significant role in the development of chronic kidney disease, and researchers are now turning to its broader role in the anging process as a whole; such as induces expression with gene therapy in mice has been shown to extend lifespan by targeting many of the same pathways as caloric restriction. Blocking Klotho has been shown to cause premature aging.

Klotho also helps to protect the brain, and contributes to more differences in intelligence than any one single gene. Research from the University of California has shown it to protect the brains of mice and improve brain function within 4 hours; and this result included young mice, old mice, and those that were models of Alzheimers disease.

In addition Klotho also plays a critical role in the inflammaging process. Inflammaging is the long term result of the chronic physiological stimulation of the innate immune system which can become damaging during the aging process.

Circulating levels of Kloto decreases with age, this decrease is associated with an increased risk of age related disease. Gene therapy with Klotho has been shown to increase lifespan in animal models, and it may improve kidney function, brain function, clear damage caused by oxidative stress, and protect against cardiovascular disease.

With the remarkable progress being made in genetics, gene therapy may play increasingly prominent and transformative roles in medicine for both humans and animals due to the potential to treat diseases and congenital disorders.

Pets can be an important part of life, they calm us, make us laugh, and create a bond of unconditional love. The company does note that all therapies are experimental, they are not approved by any regulatory body, and they make no claims that outcomes will be positive or beneficial.

IHS Pets is the veterinary wing of Integrated Health Systems, BioViva Sciences exclusive partner. IHS connects with doctors and patients who are interested in the power of gene therapy to pave the way to healthy aging and longevity.

Read more here:
IHS Pets: Bringing Cell And Gene Therapy To Cats, Dogs & Horses - Anti Aging News

Recommendation and review posted by Bethany Smith

Hansa grants Sarepta exclusive license to develop and promote imlifidase as a potential pre-treatment prior to the administration of gene therapy in Duchenne muscular dystrophy and Limb-girdle muscular dystrophy, for patients with neutralizing antibodies (NAbs) to adeno-associated virus (AAV).

Under the terms of the license: Hansa will receive a USD 10 million upfront payment and is eligible for up to USD 397.5 million in development, regulatory and sales milestone payments. Hansa will book all sales of imlifidase and would be eligible for royalties in the high single-digits to mid-teens on any gene therapy sales enabled through pre-treatment with imlifidase in NAb-positive patients.

Lund, Sweden July 2, 2020. Hansa Biopharma (Hansa), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, announced today that it has entered into an agreement with Sarepta Therapeutics Inc. (Sarepta), the leader in precision genetic medicine for rare diseases, through which Sarepta is granted an exclusive, worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy treatment in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD). The pre-treatment is intended for patients with pre-existing neutralizing antibodies (NAb-positive patients) to adeno-associated virus (AAV), the technology that is the basis for Sareptas gene therapy products.

Sarepta will be responsible for conducting pre-clinical and clinical studies with imlifidase and any subsequent regulatory approvals. Sarepta will also be responsible for the promotion of imlifidase as a pre-treatment to Sareptas gene therapies following potential approval.

Under the terms of the agreement, Hansa will receive a USD 10 million upfront payment, and is eligible for a total of up to USD 397.5 million in development, regulatory and sales milestone payments. Hansa will book all sales of imlifidase, and earn high single-digit to mid-teens royalties on Sareptas incremental gene therapy sales when treating NAb-positive patients enabled through pre-treatment with imlifidase.

Sren Tulstrup, President & CEO of Hansa Biopharma comments,We see significant potential for our enzyme technology in the gene therapy space overall, and we are excited to partner with Sarepta, a leading player in the field, to use the unique features of imlifidase to potentially enable gene therapy treatment in patients who today arent eligible for these breakthrough therapies due to pre-existing neutralizing antibodies in two conditionswith a very high unmet medical need.

Doug Ingram, President & CEO, Sarepta Therapeutics said,As we expand our leadership position in genetic medicine and build out our gene therapy engine, one of Sareptas central ambitions is to find scientific solutions that bring our potentially life-saving therapies to the greatest number of the rare disease patients we serve. One of the current limitations of gene therapy is the inability to treat patients who have pre-existing neutralizing antibodies to the AAV vector. While our AAVrh74 vector has been associated with a low screen out rate for neutralizing antibodies, even that low rate is inconsistent with our mission.

In pre-clinical and clinical models, Hansas technology has shown the ability to clear the IgG antibodies that prevent dosing AAV-based gene therapies. If successful, this could offer the potential of extending our gene therapy treatments to DMD and LGMD patients who would otherwise have been denied access due to pre-existing antibodies.

Hansa Biopharma will be hosting a conference call with President & CEO Sren Tulstrup, CSO & COO Christian Kjellman and CFO Donato Spota.

Conference Call Partnership agreement with Sarepta TherapeuticsA conference call will take place July 2nd, 2020 at 10:00am CET. The audio cast will be recorded and subsequently be available on the Hansa website https://hansa.eventcdn.net/202007

Participants dial-in numbersSE: + 46 81 241 09 52UK: + 44 203 769 6819US: + 1 646 787 0157

This is information that HansaBiopharma AB is obliged to makepublic pursuant to the EU MarketAbuse Regulation.

About imlifidaseImlifidase is a unique antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets IgG and inhibits IgG-mediated immune response. It has a rapid onset of action, cleaving IgG-antibodies and inhibiting their activity within hours after administration. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020.Hansa has also reached an agreement with the FDA on a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients in the U.S. and has three ongoing phase 2 trials in autoimmune diseases and post-transplant indications.

About gene therapy and neutralizing antibodiesGene therapy is a growing and revolutionizing treatment technology in which healthy gene sequences are inserted into cells of a patient. The treatments are potentially curative in monogenic diseases like hemophilia and muscular dystrophy through a single dose. Harmless recombinant viruses are used to carry the healthy genes into the cell. Due to the partial viral origin of the gene therapy constructs, a certain subset of patients carry neutralizing anti-AAV antibodies towards gene therapy products, depending on what AAV serotype being used, forming a barrier for treatment eligibility.Antibodies prevent effective transfer of healthy gene sequence and can be a safety concern. Imlifidase as a pre-treatment may have the potential to eliminate neutralizing antibodies prior to gene therapy. Similarly, imlifidase may have the potential to enable any potentially necessary re-dosing of gene therapy for all patients.

About Duchenne Muscular Dystrophy (DMD)Duchenne muscular dystrophy is a rare genetic disease caused by mutation in the DMD gene, encoding for the protein dystrophin. Duchenne is an irreversible, progressive disease that causes the muscles in the body to become weak and damaged over time. It is eventually fatal and there is no cure. DMD affects one in 3,500 to 5,000 males born worldwide (approximately 400-500 annual cases in the US) and causes muscles in the body to become weak and most patients use wheelchair by the age of 12.

About Limb-Girdle Muscular Dystrophy (LGMD)Limb-girdle muscular dystrophy or (LGMD) is a genetically and clinically heterogeneous group of rare muscular dystrophies. It is characterised by progressive muscle wasting which affects predominantly hip and shoulder muscles. LGMD has an autosomal pattern of inheritance and currently has no known cure or treatment. It can be caused by a single gene defect that affects specific proteins within the muscle cell, including those responsible for keeping the muscle membrane intact. LGMD has a global prevalence of approximately 1.63 per 100,000 individuals worldwide.

For further information, please contact:Klaus Sindahl, Head of Investor RelationsHansa Biopharma Mobile: +46 (0) 709-298 269E-mail: klaus.sindahl@hansabiopharma.com

About Hansa BiopharmaHansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.The Companys lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020. Hansas research and development program is advancing the next generation of the Companys technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.

View original post here:
Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in se...

Recommendation and review posted by Bethany Smith

The report covers the forecast and analysis of the Cell and Gene Therapy Consumables market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the Cell and Gene Therapy Consumables market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Cell and Gene Therapy Consumables market on a global level.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10172657

In order to give the users of this report a comprehensive view of the Cell and Gene Therapy Consumables market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are bench marked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new service & product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the Cell and Gene Therapy Consumables market by segmenting the market based on product type, application/therapeutics, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

A rise in the awareness about the gene & cell therapies will propel the market growth during the period from 2019 to 2027. Nevertheless, conducting randomized control tests will inhibit the expansion of the market during the forecast timeline. However, the growing trend for treating neurodegenerative ailments through the use of gene treatment will proliferate the market growth over the forecast period.

The expansion of the market during the forecast timespan is owing to the high frequency of chronic ailments including cancer and heart disorders. Apart from this, inflation in the occurrence of these disorders produces lucrative demand for enhanced therapies and this will culminate in the market demand over the forecast time span.

Request For Full Report:https://www.kennethresearch.com/sample-request-10172657

Based on the product type, the market is sectored into Kits & Buffers, Diagnostic Assay, Culture Medium, and Cryopreservation Media. Application/ Therapeutics- wise, the market for cell and gene therapy consumables are classified into Cardiovascular, Urology, Dermatology, Critical Care, Respiratory, Endocrine & Metabolic, Neuroscience, Hematology & Oncology, Obstetrics, Immunology, and Gastroenterology.

Some of the key players in the market include Amgen Inc., ATLANTA BIOLOGICALS, bluebird bio, Inc., Cook, Dendreon Pharmaceuticals, LLC, Fibrocell Science, Inc., General Electric, Kolon TissueGene, Inc., Orchard Therapeutics plc., Pfizer, Inc., PromoCell GmbH, RENOVA THERAPEUTICS, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Vericel, Helixmith Co., Ltd., and Vitrolife.

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

Original post:
Cell And Gene Therapy Consumables Market Size, Share And Top Key Players During 2020-2027 Bulletin Line - Bulletin Line

Recommendation and review posted by Bethany Smith

No matter how many molecules he threw at them, Paul Tesar couldnt get the brain cells to survive. Or he got them to survive, but then to everyones bafflement they still couldnt do what they were supposed to.

Tesar, a professor of innovative therapeutics at Case Western University, had spent years building stem cell models for multiple sclerosis, growing brain organoids in dishes and then seeing what small molecules restored myelin production. Now he was trying to do the same for other myelin diseases, particularly an ultra-rare genetic condition called Pelizaeus-Merzbacher disease, where a single mutation leads to the death of the myelin-producing neurons, called oligodendrocytes, and can kill patients in infancy.

Weve screened many thousands of small molecule compounds, Tesar toldEndpoints News. But we could not get them to restore function.

Then Tesar got an email from Ionis, the California biotech that had just used an RNA-modifying technology called antisense to build Spinraza, the first FDA-approved drug for the genetic neurological disorder spinal muscular atrophy.

Now, in a study published inNature,Tesar and Ionis have shown they can use a single dose of drug built from that technology to keep those neurons both alive and well-functioning and treat the disease at least in mice. The publication isnt groundbreaking, antisense researchers say, but it shows for the first time that antisense can be used to effectively target oligodendrocytes, an insight its authors hope will open up other rare myelin disorders to therapy.

Its not that its different than everything thats been done before, but it goes further than everything thats gone before, Jon Watts, a professor at the RNA Therapeutics Institute at UMass Medical School who is not affiliated with Ionis or the paper, told Endpoints, both in terms of duration of effect after a single dose, and the real focus in getting the biology, the therapeutic effect in oligodendrocytes.

The applicability to the most famous and common of myelin disorders, multiple sclerosis, is limited, researchers say, both because the therapy relied on having a specific gene to target and because the paper doesnt prove you can get an effect on the peripheral nervous system. Still, Berit Powers, an assistant director at Ioniss neurology research department and a co-author, pointed to several other genetic myelin disorders, known as leukodystrophies. That includes an Ionis program on Alexander disease, a rare childhood condition with Parkinsons-like symptoms.

Were certainly exploring the potential of ASOs in non-monogenic conditions like MS, Powers told Endpoints, using a shorthand for antisense oligonucleotides. But that work is very new.

This is hardly Tesars first foray into biotech. In 2015, he showed in Naturehow certain small molecules could regenerate myelin the holy grail for an MS therapy and founded Convelo Therapeutics around that work. Last year, they partnered with Genentech for an undisclosed sum and an exclusive option to acquire the company.

Myelin is a fatty substance that coats neurons, insulating them and helping electric currents pass through. Tesars lab was broadly interested in the question of why myelin fails, both in MS and rare diseases, and about 7 years ago he got a grant to work from the PMD Foundation.

First, Tesar built stem cell models of the disease, figuring out how different mutations in a single gene, called PLP1, lead oligodendrocyte progenitor cells (the stem cell-like cells that will become oligodendrocytes) to create a toxic RNA and a mutated protein that kills them soon after they differentiate. Then, he tried to suppress that gene with different chemicals, eventually testing over 3,000 different compounds.

He was able to eventually get the oligodendrocytes to survive, but to his surprise, they didnt produce myelin as they should. The surviving cells still couldnt properly function, revealing, he wrote in a 2018 Cell paper a second phase of pathology. A hypothetical treatment, he argued, would have to both keep progenitor cells alive and then treat the survivors in a way that induces myelination.

With antisense, he and Powers Ionis team were able to do both. Antisense oligonucelotides consist of strands of RNA that are a mirror image of the RNA you want to target. The mirror binds to and silences, or turns off, that gene. In the study, the researchers confirmed that PLP1 was disease-causing by knocking out the gene in cell lines with CRISPR. Then they injected mice with antisense strands through the spinal cord, the same way Spinraza is delivered. (You cant use CRISPR to treat the disease in humans, because theres no good way yet of delivering it.)

Powers and Tesar were unsure if they would be able to target oligodendrocytes and progenitor cells. What they found, though, was complete restoration of oligodendrocytes and a profound rescue of neurological function. Myelin, too, was finally restored. Mice that died after 3 weeks now lived for over 200 days.

Ionis hasnt licensed the drug and its unclear yet the implications for other diseases, but researchers say the results could translate into humans quickly, at least by drug development standards.

I do think its very rapidly translatable, Watts said. Based on the data theyre showing here, and based on the unmet need, this appears to be something that could be translated pretty quickly into a Phase I trial.

The rest is here:
Ionis, leading MS researcher throw antisense at a new type of brain cells - Endpoints News

Recommendation and review posted by Bethany Smith

The government unveiled its plans to invest 2.8 trillion won ($2.3 billion) in developing new key technologies to foster the bio-health industry over the next decade.

The Ministries of Health and Welfare, Science and ICT, and Trade, Industry and Energy said on Friday that two interagency projects -- new drug development and regenerative medicine technology development -- had passed the preliminary feasibility study last month.

The two national projects are part of the Bio-Health Industry Innovation Strategy announced by the government in May last year.

In pursuing new drug development as a state project, the government will provide step-by-step support, starting from basic research, going through nonclinical and clinical trials, and reaching test manufacture and mass production.

According to the viability study, the project will likely create 2.1 trillion won in industrial production for 10 years from 2021, to emerge as the largest R&D project to be conducted by the Ministry of Health and Welfare.

The three ministries said they plan to support the project by abolishing barriers as if they were one ministry. To this end, they have established a unified administrative system for the project by building up their capabilities, providing integrated consultation and support customized to the needs of universities, research institutions, and businesses.

Through the project, the government aims to develop blockbuster new drugs, each with annual sales of more than 1 trillion won ($830 million) over the next decade while enhancing the pharmaceutical industry's competitiveness.

Concerning the development of regenerative medicine technology, the government will provide support throughout the period, from the core basics and the original technology to the clinical stage of therapeutic and therapeutic technologies for regenerative medicines.

The field of regenerative medicine, despite expectations as a future medical technology, has experienced limitations in developing new technologies because of the legal system.

After the National Assembly passed the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals last year, research and development conditions and ecosystems for the regenerative medicine field have made marked improvement.

Encouraged by the brighter prospect, the government has decided to invest 595.5 billion won in this area for 10 years from 2021.

It plans to focus on strengthening the technological competitiveness of stem cell therapy products and core technologies with high potential for future growth, such as gene therapy and tissue engineering materials.

"Through the development of the bio-health industry, we will develop innovative new drugs to treat rare, incurable diseases, protect health sovereignty through localization of pharmaceuticals and medical technologies, and strengthen public health," said Im In-taek, director-general of the Health Industry Policy Bureau in the health and welfare affairs ministry.

Based on the results of the recent preliminary feasibility study, the three related ministries will go all out for the project's success, Im added.

corea022@docdocdoc.co.kr

< Korea Biomedical Review, All rights reserved.>

Originally posted here:
Korea to invest 2.8 trillion in promoting bio-health sector - Korea Biomedical Review

Recommendation and review posted by Bethany Smith

New York, July 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Brain Tumor Therapeutics Market Research Report by Type, by Therapy - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05913675/?utm_source=GNW

On the basis of Type, the Brain Tumor Therapeutics Market is studied across Glioblastoma, Meningioma, and Pituitary Tumors.

On the basis of Therapy, the Brain Tumor Therapeutics Market is studied across Gene Therapy, Immunotherapy, and Tissue Engineering.

On the basis of Geography, the Brain Tumor Therapeutics Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Brain Tumor Therapeutics Market including GlaxoSmithKline PLC, Johnson & Johnson, AstraZeneca PLC, Bristol-Myers Squibb Co, Pfizer Inc., Amgen Inc., Bayer AG, Eisai Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., and Novartis AG.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Brain Tumor Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Brain Tumor Therapeutics Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Brain Tumor Therapeutics Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Brain Tumor Therapeutics Market?4. What is the competitive strategic window for opportunities in the Global Brain Tumor Therapeutics Market?5. What are the technology trends and regulatory frameworks in the Global Brain Tumor Therapeutics Market?6. What are the modes and strategic moves considered suitable for entering the Global Brain Tumor Therapeutics Market?Read the full report: https://www.reportlinker.com/p05913675/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More here:
The Global Brain Tumor Therapeutics Market is expected to grow from USD 2,252.58 Million in 2019 to USD 3,420.14 Million by the end of 2025 at a...

Recommendation and review posted by Bethany Smith

The Ample Market Research Added A new industry research report that focuses on Cancer Gene Therapy Market and delivers in-depth market analysis and future outlook of Cancer Gene Therapy market. The study covers significant data which makes the research report a handy resource for managers, analysts, industry experts, and other key people get ready-to-access and self-analyzed study along with graphs and tables to help understand market trends, drivers and market challenges.

This is the latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions.

The report begins with a brief introduction and market overview of the Cancer Gene Therapy industry followed by its market scope and size. Next, the report provides an overview of market segmentation such as type, application, and region. The drivers, limitations, and opportunities for the market are also listed, along with current trends and policies in the industry.

Latest Sample Copy of this Cancer Gene Therapy Market Report:https://www.amplemarketreports.com/sample-request/global-cancer-gene-therapy-market-1770310.html

The report offers an extensive analysis of key drivers, leading market players, key segments, and regions. Besides this, the experts have deeply studied different geographical areas and presented a competitive scenario to assist new entrants, leading market players, and investors to determine emerging economies. These insights offered in the report would benefit market players to formulate strategies for the future and gain a strong position in the global market.

The key players profiled in this report include: Adaptimmune, Bluebird bio, Celgene, Shanghai Sunway Biotech, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, Altor BioScience, Amgen, Argenx, BioCancell, GlaxoSmithKline, Merck, OncoGenex Pharmaceuticals, Transgene

The key product type of Cancer Gene Therapy market are: Oncolytic Virotherapy, Gene Transfer, Gene-Induced Immunotherapy

The end users/applications listed in the report are: Hospitals, Diagnostics Centers, Research Institutes

The report provides a detailed study of the growth rate of every segment with the help of charts and tables. Furthermore, various regions related to the growth of the market are analyzed in the report.

These regions include: North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy), Other Country (Middle East, Africa, GCC)

Analysts have revealed that the Cancer Gene Therapy market has shown several significant developments over the past few years. The report offers sound predictions on market value and volume that can be beneficial for the market players, investors, stakeholders, and new entrants to gain detailed insights and obtain a leading position in the market.

Get Complete Report in your Inbox within 24 hours Now at : https://www.amplemarketreports.com/buy-report.html?report=1770310&format=1

The research presents the performance of each player active in the Cancer Gene Therapy market. It also offers a summary and highlights the current advancements of each player in the market. This piece of data is a great source of study material for the investors and stakeholders interested in the market. In addition, the report offers insights on suppliers, buyers, and merchants in the market. Along with this, a comprehensive analysis of consumption, market share, and growth rate of each application is offered for the historic period.

Cancer Gene Therapy market Following Details Segment by Table of Contents:

1 Cancer Gene Therapy market Overview

2 Manufacturers Profiles

3 Cancer Gene Therapy Market Competition, by Players

4 Cancer Gene Therapy Market Size by Regions

5 North America Cancer Gene Therapy Revenue by Countries

6 Europe Cancer Gene Therapy Revenue by Countries

7 Asia-Pacific Cancer Gene Therapy Revenue by Countries

8 South America Cancer Gene Therapy Revenue by Countries

9 The Middle East and Africa Cancer Gene Therapy Press by Countries

10 Cancer Gene Therapy market Segment by Type

11 Cancer Gene Therapy Market Segment by Application

12 Cancer Gene Therapy Market Size Forecast

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

Request a discount on standard prices of this premium research: https://www.amplemarketreports.com/discount-request/global-cancer-gene-therapy-market-1770310.html

You can also get individual chapter wise section or region wise report versions like North America, Europe or Asia or Country like US, UK, China and other.

About Ample Market Research

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Attention to detail, consistency, and quality are elements we focus on. However, our mainstay remains to be knowledge, expertise, and resources to make us industry players.

Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to deliver reports that have the perfect concoction of useful data.

Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Us

Ample Market Research & Consulting Private Limited

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: sales@amplemarketreports.com

Website: http://www.amplemarketreports.com

Follow this link:
Cancer Gene Therapy Market Will Generate Massive Revenue In Future - A Comprehensive Study On Key Players Adaptimmune, Bluebird bio, Celgene, Shanghai...

Recommendation and review posted by Bethany Smith